


OPIOIDS Dr. Edwin Chapman

BACKGROUND

Dr. Edwin Chapman is a physician with more than 40 years of practice in Internal Medicine and Addiction Medicine in Washington, DC. Dr. Chapman's work centers around integrating behavioral health into primary care with a focus on racial disparities and health inequities. He is an active participant as a subject matter expert for the IPRO QIN-QIO and has shared his knowledge and expertise through various educational offerings. He is nationally renowned and has appeared before Congress, as well as organizations such as SAMHSA, ASAM, Howard University, Maryland Governor's Council, and the District of Columbia. He is currently involved with the QIN-QIO and the Opioid Response Network in developing a framework for education on substance use disorder, reducing stigma, and opioid use harm.



The District of Columbia is a unique entity that receives federal funding but lacks access to state or municipal funding sources to help combat the opioid crisis. Within DC, Wards 5, 7, & 8, which Dr. Chapman's practice serves, account for >60% of the city's overdose deaths, but only 35% of its population. Overdose deaths in DC occur


APPROACH

Dr. Chapman's approach to addressing the opioid crisis Apart from working with the QIN-QIO, Dr. Chapman has in the DC area includes acting as a staunch advocate for advocated for patients by: Testifying before the US Congressional Addiction all individuals with substance abuse disorders, providing access to treatment options for his patients, and serving Treatment and Recovery Caucus. as a subject matter expert and resource for his colleagues, Being interviewed by national news outlets such as peers, and others working to advance equity in substance use disorder treatment. Toward that end, he has partnered by African American patients attempting to access with IPRO QIN-QIO on a number of initiatives, including:

- Assisting in the development of a tool for other community-based physicians: Reimbursement & Resources for Screening & Supporting Patients with Substance Use Disorder.
- Helping to educate healthcare providers as a speaker in IPRO QIN-QIO educational events such as: Integrating Behavioral Health into Primary Care and Addressing Health Disparities to Reduce Opioid Use Harm.

In recognition of integrating behavioral health into primary care with a focus on racial disparities and health inequities.

Internal Medicine and Addiction Medicine in Washington, DC




predominantly among Black males aged 50 – 70. This demographic dovetails with Dr. Chapman's practice, which skews toward Medicare, Medicaid, or dual eligible beneficiaries. To address these issues in his practice and raise awareness across the broader healthcare landscape, Dr. Chapman collaborated with the IPRO QIN-QIO as well as community based organizations including Live.Long.DC., Opioid Response Network, and District Addiction Consultation Services. In addition, Dr. Chapman is committed to improving access to treatment and interventions for harm reduction for opioid use disorders by increasing the use of telemedicine and recognizing the impact of addiction as a social determinant of health.

- Axios and PBS NewsHour regarding the struggles faced substance use disorder treatment.
- Successfully lobbying for an increase in buprenorphine dosing limits in DC.


This material was prepared by the IPRO QIN-QIO, a Quality Innovation Network-Quality Improvement Organization, under contract with the Centers for Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services (HHS). Views expressed in this material do not necessarily reflect the official views or policy of CMS or HHS, and any reference to a specific product or entity by CMS or HHS. Publication #12SOW-IPRO-QIN-T2-A3-24-1439 05/30/24 v1

RESULTS

- Number of Naloxone kits distributed in the DC area: increase of 32% from FY22 to FY23
- Number of suspected overdoses reversed with Naloxone: 5,267 (Metropolitan Police Department of DC and community partners data from 10/19 -7/23)




Medicare claims data as visualized on IPRO QIN-QIO's dashboard shows a steady decline in opioid prescribing within DC when comparing January – June 2019 to January – June 2023.



CONCLUSIONS

Dr. Chapman's dedication to his patients and to all those who struggle to access substance use disorder treatment, particularly populations that are affected by social determinants of health, provides a model for successfully integrating substance use disorder treatment into a primary care practice. His willingness to share his expertise through the IPRO QIN-QIO helps to amplify


his message and offers much needed peer education to providers throughout IPRO's geographically diverse region. His willingness to continue to act as a subject matter expert for the QIN-QIO will support further resource development, clinician awareness, and education in the area of opioid misuse.



 Number of community partners working with IPRO QIN-QIO to provide outreach in DC: 40 (to date)

 Certified number of DC-area treatment providers: 33 (to date) in a 10 square mile area

• Number of referrals made to recovery support services: 2,398 (2023)



Number of Drug Overdoses due to Opioid Use by **Race/Ethnicity and Year**

Source: LiveLongDC website

| ~ | | | | Select St | ate | Naloxone | e Prescribed? | |
|----------------------------------------------------|----------------|---------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|
| | | | Rates within Color Band* | DC. | ٠ | None | | • |
| North and a set time of the color bands are timed | by performance | 0.00 to 10.32 12.72 to 13.54 15.84 to 18.24 20.41 to 28.42 31.16 to 31.16 | | | Time Period 1/1/2021 through 6/30/2021 (Interval 5) 7/1/2021 through 12/31/2021 (Interval 6) 1/1/2022 through 6/30/2022 (Interval 7) 7/1/2022 through 6/30/2022 (Interval 8) 1/1/2023 through 6/30/2023 (Interval 9) Select 90-Day Average MME** Tier Any Opioid 90 - 119MME 120 - 239MME 240MME Higher More Information "morphine milligram equivalents | | | |
| | | | | 1001p | contraction of the | ranitendrausa | 2012010412 | |
| ilizing Opioids Per 1,000 by County | F | Percent Char | nge in Opioid (| ounty Ra | te betw | een Ava | ailable Tin | ne |
| ilizing Opioids Per 1,000 by County | F | Percent Char | | County Ra Is for Any | | een Ava | ailable Tin | ne |
| | F | | Interva | Is for Any | Opioid | nterva Int | terva Interva | Interv |
| 13.54 | | | Interva Interva Int I 2 vs. 1 I 3 | Is for Any erva Interva vs. 2 14 vs. 3 | Opioid Interval I 5 vs. 4 | nterva Int 6 vs. 5 7 | terva Interva | Interv 19 vs. |
| 13.54 | State | County | Interva Interva Int 12 vs. 1 13 15.99% -8. | Is for Any erva Interva vs. 2 4 vs. 3 10% 18.42% | Opioid Interval 5 vs. 4 -5. \$ 6% | nterva Int 6 vs. 5 7 1. 3 2% -8. | terva Interva Vs. 6 18 vs. 7 | Interv 19 vs. |
| 13.54 15.84 10.32 | State | County Ward 1 | Interva Interva Int I 2 vs. 1 I 3 15.99% -8. 4.96% 15. | Is for Any erva Interva vs. 2 4 vs. 3 \$0% 18.82% \$4% 0.87% | Opioid Interval I 5 vs. 4 -5.\$6% - -5.\$4% - | nterva Int 6 vs. 5 7 1. 8 2% -8. 7. 9 7% 23. | terva Interva vs. 6 18 vs. 7 45% 20.\$3% | Interv 19 vs. 0.209 -8.009 |
| 13.54 15.84 10.32 12.72 | State | County Ward 1 Ward 2 | Interva Interva Int 12 vs. 1 13 15.99% -8. 4.96% 15. -4.95% -9, | Is for Any erva Interva vs. 2 14 vs. 3 \$0% 18.\$2% \$4% 0.\$7% \$7% 15.\$9% | Opioid Interval I 5 vs. 4 I -5.\$6% - -5.\$4% - 12.\$4% 1 | nterva Int 6 vs. 5 7 1. 3 2% -8, 7. 3 7% 23, 7. 8 2% 22, | terva Interva vs. 6 18 vs. 7 45% 20.\$3% \$7% -6.\$4% | 19 vs. 0.269 -8.001 49.669 |
| 13.54 15.84 10.32 12.72 20.41 | State | County Ward 1 Ward 2 Ward 3 | Interva Interva Int 12 vs. 1 13 15.99% -8. 4.96% 15. -4.96% -9. 11.72% -2. 12.96% -3. | Is for Any erva Interva vs. 2 14 vs. 3 00% 18.02% 24% 0.057% 24% 15.90% 04% 6.02% | Opioid Interval I 5 vs. 4 -5.\$6% -5.\$4% 12.\$4% 15.\$1% 15.\$1% | nterva Int 6 vs. 5 17 1.32% -8 7.37% 23 7.32% 23 5.99% 10 4.36% -8 | terva Interva vs. 6 18 vs. 7 46% 20.\$3% \$7% -6.\$4% \$0% 35.\$2% \$9% 17.\$3% \$7% 18.\$3% | 1 interv 19 vs. 0.209 -8.001 49.009 7.909 2.379 |
| 13.54 15.84 10.32 12.72 | State | County Ward 1 Ward 2 Ward 3 Ward 4 Ward 5 Ward 6 | Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interv | Is for Any erva Interva vs. 2 4 vs. 3 00% 18.92% 34% 0.87% 34% 6.82% 98% -5.90% 5% -2.88% | Opioid Interval I 5 vs. 4 -5.\$696 -5.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$406 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$496 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 12.\$406 1 | nterva Int 6 vs. 5 7 1.#296 -8 7.#296 23 7.#296 22 5.#996 10 4.#696 -8 2.#596 14 | terva Interva vs. 6 18 vs. 7 45% 20.\$3% \$7% -6.\$4% \$0% 35.\$2% \$9% 17.\$3% \$7% 18.\$3% \$1% -5.\$3% | 1nterv 19 vs. 0.289 -8.009 49.099 2.379 0.399 |
| 13.54 15.84 10.32 12.72 20.41 18.24 | State DC | County Ward 1 Ward 2 Ward 3 Ward 4 Ward 5 | Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interva Interv | Is for Any erva Interva vs. 2 14 vs. 3 \$0% 18.\$2% \$4% 0.\$7% \$4% 15.\$9% \$4% 6.\$2% \$6% -2.\$6% \$4% -0.\$4% | Opioid Interval I 5 vs. 4 -5.\$6% -5.\$4% 12.\$4% 12.\$4% 12.\$4% 12.\$0% 12.\$0% 12.\$0% | nterva Int 6 vs. 5 17 1.32% -8 7.32% 23 7.32% 23 5.69% 10 4.36% -8 2.85% 14 1.39% -6 | terva Interva vs. 6 18 vs. 7 46% 20.\$3% \$7% -6.\$4% \$0% 35.\$2% \$9% 17.\$3% \$7% 18.\$3% | 1nterv 19 vs. 0.289 -8.009 49.099 2.379 0.399 |

-3.48% -0.48% -9.44% -3.43% -6.46% 16.44% 10.40% 4.42%